CD274 and cancer: Variability in cut-off points, antibody performance, inter-user and inter-assay inconsistencies led to technical challenges in incorporating PD-L1 immunohistochemistry as a “one-size-fits-all” biomarker applicable across the entire cancer and immune checkpoint inhibitor conglomerate.